Y-mAbs Therapeutics, Inc. Aktie News

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-Investor Relations Michael Rossi - President and Chief Executive Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Bill Maughan...

The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 2024 American Society of Clinical O...

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his res...

Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the quarter and full year ended December 31, 2023.

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment commu...